We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+12.78%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$208M
AUM Growth
+$29.3M
Cap. Flow
+$24.3M
Cap. Flow %
11.67%
Top 10 Hldgs %
53.69%
Holding
72
New
35
Increased
16
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.44M
2
DERM
Dermira, Inc.
DERM
+$4.69M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$4.6M
4
IRIX icon
IRIDEX
IRIX
+$4.41M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.88M

Top Sells

Rank Stock Value
1
FOLD
Amicus Therapeutics
FOLD
+$9.36M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$6.39M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$5.51M
4
SBBP
Strongbridge Biopharma plc.
SBBP
+$4.51M
5
IMMU
Immunomedics Inc
IMMU
+$4.43M

Sector Composition

Rank Sector Weight
1 Healthcare 73.3%
2 Technology 1.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKTX
51
Akari Therapeutics
AKTX
$12.9M
$446K 0.21%
41
+18
+78% +$232K
CDNA icon
52
CareDx
CDNA
$2.48B
$279K 0.13%
+64,627
New +$299K
CRDF icon
53
PUT
Cardiff Oncology
CRDF
$72.7M
$236K 0.11%
+722
New +$249K
DXTR
54
DELISTED
Dextera Surgical Inc.
DXTR
$232K 0.11%
+128,958
New +$264K
CYTR
55
PUT
DELISTED
CytRx Corp
CYTR
$223K 0.11%
+16,667
New +$277K
AUDC icon
56
AudioCodes
AUDC
$249M
$189K 0.09%
+45,035
New +$186K
RLYP
57
CALL
DELISTED
RELYPSA INC COM
RLYP
$185K 0.09%
+10,000
New +$176K
IMMU
58
CALL
DELISTED
Immunomedics Inc
IMMU
$136K 0.07%
+58,600
New +$196K
CBMX
59
DELISTED
CombiMatrix Corporation
CBMX
$136K 0.07%
47,431
– –
MNKD icon
60
PUT
MannKind Corp
MNKD
$1.17B
$104K 0.05%
18,000
-12,000
-40% -$74.2K
CEMI
61
DELISTED
Chembio diagnostics, Inc.
CEMI
$100K 0.05%
+12,180
New +$94.9K
ONSIW
62
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$45K 0.02%
+96,833
New +$37.1K
ONSIZ
63
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$44K 0.02%
+96,833
New +$50.9K
PTX
64
PUT
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$28K 0.01%
+6,280
New +$41K
EXEL icon
65
Exelixis
EXEL
$13.8B
– –
-320,897
Closed -$1.28M
VANI icon
66
PUT
Vivani Medical
VANI
$115M
– –
-2,083
Closed -$242K
TLGT
67
DELISTED
Teligent, Inc
TLGT
– –
-10,341
Closed -$507K
SBBP
68
DELISTED
Strongbridge Biopharma plc.
SBBP
– –
-1,063,747
Closed -$4.51M
NVIV
69
PUT
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
-1
Closed -$140K
CPXX
70
DELISTED
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
– –
-500,000
Closed -$5.51M
CRDC
71
DELISTED
CARDICA INC COM NEW (DE)
CRDC
– –
-120,958
Closed -$431K
1 2
3

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2016 Portfolio in Review

As of Q2 2016, Acuta Capital Partners held 72 positions worth $208M, up 16% from $179M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Acuta Capital Partners deployed $24.3M of net new capital in Q2 2016, opening 35 new positions and adding to 16 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 69% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Amicus Therapeutics, an estimated $9.36M trimmed.

  • Acuta Capital Partners's largest Q2 2016 buy was BioMarin Pharmaceuticals: 64,000 shares worth $4.98M.
  • Acuta Capital Partners added most to Iovance Biotherapeutics in Q2 2016, an estimated $4.6M increase.
  • Acuta Capital Partners's biggest Q2 2016 reduction was Amicus Therapeutics, cutting an estimated $9.36M.
  • Acuta Capital Partners fully exited CELATOR PHARMACEUTICALS INC. COMMON STOCK in Q2 2016, selling an estimated $5.51M.
  • Acuta Capital Partners's ten largest holdings make up 54% of its $208M portfolio in Q2 2016.
  • Acuta Capital Partners opened 35 new positions and closed 7 in Q2 2016.
  • Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $208M.

Based on Acuta Capital Partners's 13F filing for Q2 2016, filed 15 Aug 2016.